抗菌药物敏感性测试适用于任何导致感染过程的生物体 如果根据对生物体的了解无法可靠预测其易感性，那么抗生素化疗？这是他的身份。 还需要进行标准化的体外抗菌药物敏感性试验，以评估针对特定细菌的新抗菌药物 与现有制剂相比的生物体群。对一种或多种抗菌剂的获得性耐药性已被发现 现在出现在感染人类的主要支原体和解脲支原体物种中，因此需要建立准确、可靠的检测方法 用这些微生物在体外测定抗菌活性的可重复方法。本文件提供了体外肉汤微量稀释和琼脂的性能、解释和质量控制指南 几种适用于肺炎支原体（肺炎支原体）的抗菌剂的稀释敏感性试验， 人型支原体（人型支原体）和解脲支原体（解脲支原体属）。本文件中的信息包括 指定的参考菌株和应获得的特定药物的预期最小抑制浓度范围 当他们被测试时。

Antimicrobial susceptibility testing is indicated for any organism that contributes to an infectious process warranting antimicrobial chemotherapy, if its susceptibility cannot be reliably predicted from knowledge of the organism?s identity. Standardized in vitro antimicrobial susceptibility tests are also needed in order to evaluate new antimicrobials against specific groups of organisms in comparison with existing agents. Acquired resistance to one or more classes of antimicrobial agents has now emerged in the major mycoplasmal and ureaplasmal species that infect humans, hence the need to establish accurate and reproducible methods to measure antimicrobial activities in vitro with these organisms.This document provides guidelines for performance, interpretation, and quality control of in vitro broth microdilution and agar dilution susceptibility tests for several antimicrobial agents suitable for use against Mycoplasma pneumoniae (M. pneumoniae), Mycoplasma hominis (M. hominis), and Ureaplasma species (Ureaplasma spp). Information in this document includes designated reference strains and the expected minimal inhibitory concentration ranges for specific drugs that should be obtained when they are tested.